Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.
Tidutamab was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors of pancreatic, gastrointestinal, lung and undetermined origin.
The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.
Prophylactic octreotide can be safely discontinued in patients with neuroendocrine tumors undergoing operation, as stopping its use has not been shown to increase the rate or duration of carcinoid crisis.
The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.
Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.
The novel somatostatin analog for the Targeted Alpha-emitter Therapy 212Pb-DOTAMTATE has demonstrated early efficacy and a tolerable safety profile in a small cohort of patients with metastatic somatostatin receptor–expressing neuroendocrine tumors irrespective of location of the primary tumor.
Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.
Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.
Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.
Retreatment with Lutathera-based peptide receptor radionuclide therapy has been shown to have an encouraging survival benefit with an acceptable safety in patients with neuroendocrine tumors.
Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.
Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.
Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).